About us

IS Pharma plc (AIM:ISPH) is a fast growing and profitable European speciality pharmaceutical company, which is traded on AIM, a market operated by the London Stock Exchange.

The strategy of the Group is to build a leading European speciality pharmaceutical company through the acquisition, integration and development of late-stage pharmaceuticals and medical devices.

Based in the UK, IS Pharma markets its products in the UK directly and internationally through a network of well established distributors. IS Pharma's marketed and development products include:

Oncology: Aloxi^® (treatment of chemotherapy induced nausea and vomiting), episil^® (for the prevention of pain associated with oral mucositis), aquoral^® (for the treatment of xerostomia).

Critical Care: Cryogesic/Dermogesic^® (cryo-analgesic), Haemopressin/Variquel^® (treatment of oesophageal varices).

Neurology: Mysoline^® (primidone), a product currently used to treat Epilepsy and which IS Pharma are developing for management of Essential Tremor, a distressing condition affecting an estimated 1 in 25 over 40 year olds for which primidone is one of only two recommended treatments, Acoranil^® (imipramine liquid), licensed to Rosemont Pharmaceuticals Ltd.

Products which are outside of the Group's core hospital focus or are in early stage of research are out-licensed, including the successful OptiFlo^® Catheter Maintenance Solutions (to Bard Limited) and micelle nanotechnology, which is incorporated into an early stage lidocaine based product for the treatment of interstitial cystitis (to Plethora Solutions Limited).

OptiFlo^® is a trademark of CR.Bard Inc or an affiliate.